Managing hypertension in patients with type 2 diabetes mellitus (Q36497767)

14 August 2017

1 reference

title

Managing hypertension in patients with type 2 diabetes mellitus (English)

1 reference

14 August 2017

arterial hypertension

0 references

1 reference

Paul P Dobesh

1

1 reference

14 August 2017

1 June 2006

1 reference

American Journal of Health-System Pharmacy

14 August 2017

1 reference

14 August 2017

63

1 reference

14 August 2017

1140-1149

1 reference

14 August 2017

12

1 reference

14 August 2017

Epidemiology of diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Diabetes, the renin-angiotensin system and heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Standards of medical care in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Diabetic nephropathy: diagnosis, prevention, and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Hypertension management in adults with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Hypertension, diabetes, and longitudinal changes in intraocular pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Incidence of diabetic retinopathy in the Barbados Eye Studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Dual blockade of the renin-angiotensin system in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Hypertension and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Treatment of cardiovascular and renal risk factors in the diabetic hypertensive

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Clinical practice. Nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The importance of blood pressure control in the patient with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Opportunities for improving the quality of hypertension care in a managed care setting

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

The urgent need to improve hypertension care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Hypertension management and control among English adults aged 65 years and older in 2000 and 2001.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

How pharmacists can assist physicians with controlling blood pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Improving blood pressure control in a pharmacist-managed hypertension clinic.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Implementation of a pharmacist-led clinic for hypertensive patients in primary care--a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Pharmacist involvement in primary care improves hypertensive patient clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

31 March 2020

Adherence to Medication

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Lifestyle modification to improve blood pressure control in individuals with diabetes: is physician advice effective?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050385

31 March 2020

Identifiers

DOI

10.2146/AJHP050385

1 reference

14 August 2017

1 reference

PubMed ID

16754740